Copyright: © 2022 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Experience of Stanford neuromodulation therapy in patients with treatment-resistant depression

Poydasheva AG1, Bakulin IS1, Sinitsyn DO1, Zabirova AH1, Suponeva NA1, Maslenikov NV2, Tsukarzi EE2, Mosolov SN2,3, Piradov MA1
About authors

1 Research Center of Neurology, Moscow, Russia

2 Moscow Research Institute of Psychiatry, Moscow, Russia

3 Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Correspondence should be addressed: Alexandra G. Poydasheva
Volokolamskoe shosse, 80, Moscow, 125367, Russia; ur.ygoloruen@avehsadyop

About paper

Author contribution: Poydasheva AG, Bakulin IS, Mosolov SN — study planning and design; Poydasheva AG, Zabirova AH — literature review; Poydasheva AG, Sinitsyn DO, Maslenikov NV, Tsukarzi EE — data acquisition and analysis; all authors — data interpretation; Poydasheva AG, Sinitsyn DO — manuscript writing; all authors — manuscript editing.

Compliance with ethical standards: the research protocol was approved by the Ethics Committee at the Research Center of Neurology (protocol № 11-1/21 of 22 December 2021); the study was conducted in accordance with the principles of the Declaration of Helsinki; the informed consent was submitted by all study participants.

Received: 2022-08-08 Accepted: 2022-08-22 Published online: 2022-08-30
|
  1. Maksimova NM, Rusyaev VYu, Uzbekov MG. Nejrobiologicheskie mexanizmy razvitiya rezistentnyx depressij. Social'naya i klinicheskaya psixiatriya. 2021; 31 (4): 71–79. Russian.
  2. Voineskos D, Daskalakis ZJ, Blumberger DM. Management of Treatment-Resistant Depression: Challenges and Strategies. Neuropsychiatr Dis Treat. 2020; 16: 221–34.
  3. Mosolov SN, Alfimov PV, Kostyukova EG. Sovremennye metody preodoleniya terapevticheskoj rezistentnosti pri rekurrentnoj depressii. V knige: S. N. Mosolov, redaktor. Biologicheskie metody terapii psixicheskix rasstrojstv. M., 2012; s. 438–73. Russian.
  4. Miron JP, Jodoin VD, Lespérance P, Blumberger DM. Repetitive transcranial magnetic stimulation for major depressive disorder: basic principles and future directions. Ther Adv Psychopharmacol. 2021; 11: 20451253211042696.
  5. Chervyakov AV, Chernyavsky AY, Sinitsyn DO, Piradov MA. Possible Mechanisms Underlying the Therapeutic Effects of Transcranial Magnetic Stimulation. Front Hum Neurosci. 2015; 9: 303.
  6. O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007; 62 (11): 1208–16.
  7. Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, et al. Effectiveness of theta burst versus highfrequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018; 391 (10131): 1683–92.
  8. Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018). Clin Neurophysiol. 2020; 131 (2): 474–528.
  9. Boes AD, Kelly MS, Trapp NT, Stern AP, Press DZ, Pascual-Leone A. Noninvasive Brain Stimulation: Challenges and Opportunities for a New Clinical Specialty. J Neuropsychiatry Clin Neurosci. 2018; 30 (3): 173–79.
  10. Berlim MT, van den Eynde F, Tovar-Perdomo S, Daskalakis ZJ. Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. Psychol Med. 2014; 44 (2): 225–39.
  11. Sehatzadeh S, Daskalakis ZJ, Yap B, Tu HA, Palimaka S, Bowen JM, et al. Unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression: a meta-analysis of randomized controlled trials over 2 decades. J Psychiatry Neurosci. 2019; 44 (3): 151–63.
  12. Fox MD, Buckner RL, White MP, Greicius MD, Pascual-Leone A. Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biol Psychiatry. 2012; 72 (7): 595–603.
  13. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008; 213 (1–2): 93–118.
  14. Antonovich BA, Maĭorova LA, Cukarzi EhEh, Mosolov SN. Neĭronnye seti sostoyaniya pokoya pri depressiyax i perspektivy primeneniya personificirovannoj TMS. Sovremennaya terapiya psixicheskix rasstrojstv. 2019; 3: 2–11. Russian.
  15. Poydasheva AG, Sinitsyn DO, Bakulin IS, Suponeva NA, Maslenikov NV, Tsukarzi EE. i dr. Opredelenie misheni dlya transkranial'noj magnitnoj stimulyacii u pacientov s rezistentnym k farmakoterapii depressivnym ehpizodom na osnove individual'nyx parametrov funkcional'noj magnitno-rezonansnoj tomografii pokoya (pilotnoe slepoe kontroliruemoe issledovanie. Nevrologiya, nejropsixiatriya, psixosomatika. 2019; 11 (4): 44–50. Russian.
  16. Sonmez AI, Camsari DD, Nandakumar AL, Voort JLV, Kung S, Lewis CP, et al. Accelerated TMS for Depression: A systematic review and meta-analysis. Psychiatry Res. 2019; 273: 770–81.
  17. Cole EJ, Stimpson KH, Bentzley BS, Gulser M, Cherian K, Tischler C, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. Am J Psychiatry. 2020; 177 (8): 716–26.
  18. Cole EJ, Phillips AL, Bentzley BS, Stimpson KH, Nejad R, Barmak F, et al. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. Am J Psychiatry. 2022; 179 (2): 132–41.
  19. Axapkin RV, Bukreeva ND, Vazagaeva TI, Kostyukova EG, Mazo GEh, Mosolov SN. Depressivnyj ehpizod, rekurrentnoe depressivnoe rasstrojstvo. Klinicheskie rekomendacii. Vzroslye. Ehlektronnoe izdanie. 2021. Dostupno po ssylke: https:// cr.minzdrav.gov.ru/recomend/301_2. Russian.
  20. Mosolov SN, Kostyukova EG, Ladyzhenskij MYa. Algoritm biologicheskoj terapii ostrogo ehpizoda rekurrentnogo depressivnogo rasstrojstva. Sovremennaya terapiya psixicheskix rasstrojstv. 2016; 3: 27–40. Russian.
  21. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134: 382–9.
  22. Hawley CJ, Gale TM, Sivakumaran T; Hertfordshire Neuroscience Research group. Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord. 2002; 72 (2): 177–84.
  23. Fekadu A, Wooderson SC, Markopoulou K, Cleare AJ. The Maudsley Staging Method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms. J Clin Psychiatry. 2009; 70 (7): 952–7.
  24. Siddiqi SH, Taylor SF, Cooke D, Pascual-Leone A, George MS, Fox MD. Distinct Symptom-Specific Treatment Targets for Circuit-Based Neuromodulation. Am J Psychiatry. 2020; 177 (5): 435–46.
  25. Loo CK, Mitchell PB, McFarquhar TF, Malhi GS, Sachdev PS. A sham-controlled trial of the efficacy and safety of twice-daily rTMS in major depression. Psychol Med. 2007; 37 (3): 341–9.
  26. Blumberger DM, Vila-Rodriguez F, Wang W, Knyahnytska Y, Butterfield M, Noda Y, et al. A randomized sham controlled comparison of once vs twice-daily intermittent theta burst stimulation in depression: A Canadian rTMS treatment and biomarker network in depression (CARTBIND) study. Brain Stimul. 2021; 14 (6): 1447–55.
  27. Fitzgerald PB, Hoy KE, Elliot D, Susan McQueen RN, Wambeek LE, Daskalakis ZJ. Accelerated repetitive transcranial magnetic stimulation in the treatment of depression. Neuropsychopharmacology. 2018; 43 (7): 1565–72.
  28. Abraham WC, Bear MF. Metaplasticity: the plasticity of synaptic plasticity. Trends Neurosci. 1996; 19 (4): 126–30.